补骨脂素灭活的1型登革病毒候选疫苗在小鼠体内的免疫原性。
Immunogenicity of a psoralen-inactivated dengue virus type 1 vaccine candidate in mice.
作者信息
Maves Ryan C, Castillo Oré Roger M, Porter Kevin R, Kochel Tadeusz J
机构信息
U.S. Naval Medical Research Center Detachment, Lima, Peru.
出版信息
Clin Vaccine Immunol. 2010 Feb;17(2):304-6. doi: 10.1128/CVI.00353-09. Epub 2009 Dec 9.
Abstract
We evaluated a novel psoralen-inactivated dengue virus type 1 (DENV-1) vaccine candidate in Mus musculus mice. Mice received intradermal alum or 5 to 10 ng of psoralen-inactivated virus. Anti-DENV-1 neutralizing antibody was detectable in 10/11 mice receiving a 10-ng dose at 90 days. Psoralen-inactivated DENV-1 is immunogenic in mice.
摘要
我们在小家鼠中评估了一种新型补骨脂素灭活的1型登革病毒（DENV-1）候选疫苗。小鼠接受皮内注射明矾或5至10纳克补骨脂素灭活病毒。在90天时，11只接受10纳克剂量的小鼠中有10只检测到抗DENV-1中和抗体。补骨脂素灭活的DENV-1在小鼠中具有免疫原性。
相似文献
1
Immunogenicity of a psoralen-inactivated dengue virus type 1 vaccine candidate in mice.
Clin Vaccine Immunol. 2010 Feb;17(2):304-6. doi: 10.1128/CVI.00353-09. Epub 2009 Dec 9.
2
Immunogenicity and protective efficacy of a psoralen-inactivated dengue-1 virus vaccine candidate in Aotus nancymaae monkeys.
Vaccine. 2011 Mar 24;29(15):2691-6. doi: 10.1016/j.vaccine.2011.01.077. Epub 2011 Feb 17.
3
Comparison of purified psoralen-inactivated and formalin-inactivated dengue vaccines in mice and nonhuman primates.
Vaccine. 2020 Apr 9;38(17):3313-3320. doi: 10.1016/j.vaccine.2020.03.008. Epub 2020 Mar 14.
4
Dengue virus photo-inactivated in presence of 1,5-iodonaphthylazide (INA) or AMT, a psoralen compound (4'-aminomethyl-trioxsalen) is highly immunogenic in mice.
Hum Vaccin Immunother. 2013 Nov;9(11):2336-41. doi: 10.4161/hv.25602. Epub 2013 Jul 8.
5
The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
Asian Pac J Allergy Immunol. 2015 Sep;33(3):182-8. doi: 10.12932/AP0508.33.3.2015.
6
Phase I Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico.
Am J Trop Med Hyg. 2018 May;98(5):1435-1443. doi: 10.4269/ajtmh.17-0627. Epub 2018 Mar 1.
7
An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques.
Am J Trop Med Hyg. 2015 Apr;92(4):698-708. doi: 10.4269/ajtmh.14-0268. Epub 2015 Feb 2.
8
The protein DIIIC-2, aggregated with a specific oligodeoxynucleotide and adjuvanted in alum, protects mice and monkeys against DENV-2.
Immunol Cell Biol. 2015 Jan;93(1):57-66. doi: 10.1038/icb.2014.63. Epub 2014 Sep 2.
9
Tetravalent dengue DIIIC protein together with alum and ODN elicits a Th1 response and neutralizing antibodies in mice.
Vaccine. 2015 Mar 17;33(12):1474-82. doi: 10.1016/j.vaccine.2015.01.074. Epub 2015 Feb 7.
10
A vaccine formulation consisting of nucleocapsid-like particles from Dengue-2 and the fusion protein P64k-domain III from Dengue-1 induces a protective immune response against the homologous serotypes in mice.
Acta Trop. 2012 Nov;124(2):107-12. doi: 10.1016/j.actatropica.2012.06.006. Epub 2012 Jun 29.
引用本文的文献
1
The Immunogenicity and Properties of a Whole-Cell ETEC Vaccine Inactivated with Psoralen and UVA Light in Comparison to Formalin.
Microorganisms. 2023 Aug 9;11(8):2040. doi: 10.3390/microorganisms11082040.
2
Psoralen inhibits hepatitis B viral replication by down-regulating the host transcriptional machinery of viral promoters.
Virol Sin. 2022 Apr;37(2):256-265. doi: 10.1016/j.virs.2022.01.027. Epub 2022 Jan 25.
3
A Review of the Pharmacological Properties of Psoralen.
Front Pharmacol. 2020 Sep 4;11:571535. doi: 10.3389/fphar.2020.571535. eCollection 2020.
4
Psoralen Inactivation of Viruses: A Process for the Safe Manipulation of Viral Antigen and Nucleic Acid.
Viruses. 2015 Nov 12;7(11):5875-88. doi: 10.3390/v7112912.
5
Immunogenic Properties of a BCG Adjuvanted Chitosan Nanoparticle-Based Dengue Vaccine in Human Dendritic Cells.
PLoS Negl Trop Dis. 2015 Sep 22;9(9):e0003958. doi: 10.1371/journal.pntd.0003958. eCollection 2015 Sep.
6
Development and evaluation of single domain antibodies for vaccinia and the L1 antigen.
PLoS One. 2014 Sep 11;9(9):e106263. doi: 10.1371/journal.pone.0106263. eCollection 2014.
7
Can biowarfare agents be defeated with light?
Virulence. 2013 Nov 15;4(8):796-825. doi: 10.4161/viru.26475. Epub 2013 Sep 25.
8
Dengue virus photo-inactivated in presence of 1,5-iodonaphthylazide (INA) or AMT, a psoralen compound (4'-aminomethyl-trioxsalen) is highly immunogenic in mice.
Hum Vaccin Immunother. 2013 Nov;9(11):2336-41. doi: 10.4161/hv.25602. Epub 2013 Jul 8.
本文引用的文献
1
Quantification of viral inactivation by photochemical treatment with amotosalen and UV A light, using a novel polymerase chain reaction inhibition method with preamplification.
J Infect Dis. 2006 Dec 15;194(12):1737-44. doi: 10.1086/509260. Epub 2006 Nov 8.
2
A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines.
Nat Med. 2006 Aug;12(8):905-7. doi: 10.1038/nm1456. Epub 2006 Jul 23.
3
Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function.
Transfusion. 2006 Jul;46(7):1168-77. doi: 10.1111/j.1537-2995.2006.00867.x.
4
The role of photochemical treatment with amotosalen and UV-A light in the prevention of transfusion-transmitted cytomegalovirus infections.
Transfus Med Rev. 2006 Jan;20(1):45-56. doi: 10.1016/j.tmrv.2005.08.004.
5
Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light.
Transfusion. 1997 Apr;37(4):423-35. doi: 10.1046/j.1537-2995.1997.37497265344.x.
6
Review of accidents caused by incomplete inactivation of viruses.
Dev Biol Stand. 1993;81:103-7.
7
Psoralen photochemistry and nucleic acid structure.
J Invest Dermatol. 1981 Jul;77(1):39-44. doi: 10.1111/1523-1747.ep12479229.
8
Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization.
J Clin Microbiol. 1985 Aug;22(2):250-4. doi: 10.1128/jcm.22.2.250-254.1985.
9
An overview of the inactivation of FMDV and the implications when residual virus is present in vaccines.
Dev Biol Stand. 1991;75:37-41.
10
Psoralen preparation of antigenically intact noninfectious rotavirus particles.
J Virol Methods. 1992 Jul;38(1):93-102. doi: 10.1016/0166-0934(92)90172-a.
Zotero 插件